Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Qyuns Therapeutics Co., Ltd. Class H ( (HK:2509) ) has issued an update.
Qyuns Therapeutics Co., Ltd. announced that its supplemental application for QX001S (SAILEXIN, Ustekinumab Injection) has been approved by the National Medical Products Administration for the new indication of treating pediatric plaque psoriasis. This approval allows the drug to be used in children and adolescents aged 6 years and above with moderate-to-severe plaque psoriasis who have not responded adequately to other treatments. This development is expected to enhance the company’s market positioning in pediatric dermatology and expand its product offerings, potentially impacting stakeholders positively by addressing unmet medical needs.
More about Qyuns Therapeutics Co., Ltd. Class H
Qyuns Therapeutics Co., Ltd. operates in the pharmaceutical industry, focusing on the development and production of therapeutic biological products. The company is known for its biosimilar drugs, including Ustekinumab Injection, which is used to treat immune-mediated inflammatory diseases.
YTD Price Performance: -7.86%
Average Trading Volume: 42,676
Technical Sentiment Consensus Rating: Strong Buy
Find detailed analytics on 2509 stock on TipRanks’ Stock Analysis page.